AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00539149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxycillin
Description: 50 mg/kg/day twice daily
Study NCT00539149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo equivalent to amoxycillin
Description: 50 mg/kg/d twice daily
Study NCT01210196 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: Cardiac MRI after 12 and 24 months.
Study NCT00976469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)
Description: 2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
Study NCT00976469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
Description: Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
Study NCT01336881 — intervention group
Intervention type: GENETIC
Intervention: RNA analysis
Study NCT01336881 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT01336881 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT01336881 — intervention group
Intervention type: GENETIC
Intervention: nucleic acid sequencing
Study NCT01336881 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study NCT03298503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task-priority strategies
Description: posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray).
Study NCT03298503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task-priority strategies
Description: posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray).
Study NCT00519896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT02139475 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Study NCT03837392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Assessment (18-26 weeks pregnant)
Description: At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
Study NCT03837392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Assessment (18-26 weeks pregnant)
Description: At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
Study NCT03837392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention and Phone Coaching Interventions
Description: ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
Study NCT03837392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Intervention and Phone Coaching Interventions
Description: ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
Study NCT03837392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum
Description: The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
Study NCT03837392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum
Description: The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
Study NCT03837392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow Up Assessments: 8 weeks postpartum
Description: The follow-up assessment at 8-weeks postpartum will be completed via phone.
Study NCT03837392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Assessments: 8 weeks postpartum
Description: The follow-up assessment at 8-weeks postpartum will be completed via phone.
Study NCT04170868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADHD Psycheducation
Description: The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone was supplied as film-coated tablets.
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to citalopram
Description: Placebo to citalopram was supplied as a capsule.
Study NCT05031650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: openCPAP
Description: Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to citalopram
Description: Placebo to citalopram was supplied as a capsule.
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to vilazodone
Description: Placebo to vilazodone was supplied as film-coated tablets.
Study NCT01473381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram was supplied as encapsulated tablets.
Study NCT02387216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: Investigational, fully human antibody targeting and inhibiting ErbB3
Study NCT02387216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: approved chemotherapy treatment for NSCLC
Study NCT02387216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: approved chemotherapy treatment for NSCLC
Study NCT02586337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT02586337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study NCT01335503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AN-PEP
Description: Endoprotease enzyme (AN-PEP)
Study NCT01335503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AN-PEP
Description: Endoprotease enzyme (AN-PEP)
Study NCT02467322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
Study NCT02467322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascitic fluid
Study NCT02467322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascitic fluid
Study NCT04678622 — intervention group
Intervention type: DEVICE
Intervention: Bioferula3D
Description: Custom splint with 3D technology classified as a custom medical device
Study NCT02254837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver PTX Drug-Eluting Stent
Study NCT00805493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Study NCT00683280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
Study NCT00683280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
Study NCT00683280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
Study NCT00683280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Twice weekly brief counseling based on public health service guidelines for quitting smoking.
Study NCT00683280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Twice weekly brief counseling based on public health service guidelines for quitting smoking.
Study NCT05031650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standardCPAP
Description: Randomized to : Standard level CPAP between 6-8 cmH2O pressure
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin hydrochloride
Description: Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Study NCT02419729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
Study NCT02419729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser
Description: SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
Study NCT02419729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Topical estrogen cream treatment: Estriol 1mg daily.
Study NCT02419729 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Estrogen
Description: Topical estrogen cream treatment: Estriol 1mg daily.
Study NCT02419729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Estrogen
Description: Placebo of topical estrogen cream.
Study NCT02419729 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo of CO2 laser
Description: SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
Study NCT02043262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reablement
Description: The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered per dose and schedule specified in the arm description.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered per dose and schedule specified in the arm description.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Free doxorubicin hydrochloride
Description: Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered per dose and schedule specified in the arm description.
Study NCT00712881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered per dose and schedule specified in the arm description.
Study NCT01869699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
Study NCT01869699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
Study NCT01767506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveillance and treatment with azithromycin of newcomer and traveler families
Description: The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
Study NCT01767506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
Study NCT02043262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The control intervention is standard home-based treatment/care in Norway.
Study NCT01027364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX (rFIXFc)
Study NCT01027364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFIX
Study NCT00002757 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Study NCT01767506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
Study NCT03091192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Study NCT00002757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT02501213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone (+/- Furosemide)
Description: Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
Study NCT00985543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
Study NCT00985543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
Study NCT02952664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUMP Monitoring
Description: A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
Study NCT02394041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
Study NCT02394041 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture with sham needles
Study NCT02751736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CJLP243
Description: Perioperative administration till postoperative weeks 3
Study NCT02751736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Perioperative administration till postoperative weeks 3
Study NCT04076020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational agent/AliveCor Kardia - Intervention
Description: Use of the relational agent and Kardia daily for 120 days.
Study NCT04076020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Use of the WebMD app daily for 120 days.
Study NCT04538924 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: extended clinical, laboratory and instrumental examination; treatment options comparison
Description: Multimodality investigation and different treatment comparison
Study NCT00245856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium injection
Description: 200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
Study NCT00245856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Titrated to INR 2-3 through study month 3
Study NCT03450681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency of the saphenous nerve before knee replacement surgery
Description: A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
Study NCT03450681 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mock incision
Description: A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
Study NCT02611544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: 6-week ACT intervention group (n=33)
Study NCT02611544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Education
Description: 6-week survivorship education group (SE; n=32)
Study NCT02611544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: enhanced usual care (EUC; n=26)
Study NCT03758027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARESS
Description: The goals of each component are as follows:~* Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~* Release endorphins - a release for the internal stress created by the emotion; and~* Self-soothe - a method of quelling and containing.
Study NCT03758027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Exercise
Description: 5-minute protocol for cravings management and affect regulation